Tokyo, Oct. 31 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059548) titled 'The Prevalence of Probable Generalized Anxiety Disorder in General Internal Medicine Clinics: A multicenter, cross-sectional study in Japan' on Oct. 31.
Study Type:
Observational
Primary Sponsor:
Institute - Viatris Pharmaceuticals Japan G.K.
Condition:
Condition - Generalized Anxiety Disorder
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To clarify the extent to which patients with probable GAD are present in general internal medicine clinics, excluding psychiatry and psychosomatic medicine.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - 1. Japanese male or female participants who are over 18 years of age or older at the time of obtaining informed consent
2. Outpatients in general internal medicine clinic
3. Outpatients visiting the internal medicine clinic regularly (at least once every 3 months) due to their diseases
4. Patients able to sign informed consent 5. Patients who are willing to participate in this study and answer the questionnaire
Key exclusion criteria - 1. Patients visiting a psychiatry or psychosomatic medicine due to their mental disorders
2. Patients with a prior or current diagnosis of dementia
3. Patients visiting a clinic unexpectedly due to only acute symptoms such as fever
4. Patients who are deemed inappropriate for participation in this study by the investigators
Target Size - 500
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2025 Year 10 Month 02 Day
Date of IRB - 2025 Year 10 Month 21 Day
Anticipated trial start date - 2025 Year 11 Month 01 Day
Last follow-up date - 2025 Year 11 Month 30 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068111
Disclaimer: Curated by HT Syndication.
